Medicxi Ventures is a venture capital firm headquartered in London, England. It was founded in 2016 by the former Index Ventures life sciences team. The company primarily invests in the life sciences industry. The firm manages two funds Medicxi Ventures 1, which concentrates on early stage companies, and Medicxi Growth 1 which concentrates on growth stage companies. The company also has offices on in Geneva and St. Heiler.
In 2019, Medicxi announced it was raising a new €350 million fund that would focus on the biotechnology industry.
Synthetic biology company that created novel DNA base pairs and uses them to incorporate novel amino acids into proteins for potential therapeutics in areas of cancer and autoimmune disorders.
An independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases.
A biotechnology company developing nanoparticle therapies to target and destroy cancer cells